A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1406-1415

  He, Simon Z ^a,b,c   Busfield, Samantha ^d   Ritchie, David S ^a,b,e,f   Hertzberg, Mark S ^g,h   Durrant, Simon ⁱ   Lewis, Ian D ^j   Marlton, Paula ^k,l   McLachlan, Andrew J ^m   Kerridge, Ian ^g   Bradstock, Kenneth F ^g   Kennedy, Glen ⁱ   Boyd, Andrew W ^i,l,n   Yeadon, Trina M ⁿ   Lopez, Angel F ^o   Ramshaw, Hayley S ^o   Iland, Harry ^p   Bamford, Simone ^d   Barnden, Megan ^d   Dewitte, Mark ^d   Basser, Russell ^d   Roberts, Andrew W ^a,b,c,f   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Research and Development Section   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f Melbourne Comprehensive Cancer Centre   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

^h PRINCE OF WALES HOSPITAL   (Australia)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^j ROYAL ADELAIDE HOSPITAL   (Australia)

^k PRINCESS ALEXANDRA HOSPITAL   (Australia)

^l UNIVERSITY OF QUEENSLAND   (Australia)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^o UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^p ROYAL PRINCE ALFRED HOSPITAL   (Australia)

more..

Author keywords

Acute myeloid leukemia (AML); Immunotherapy; Interleukin 3 (IL 3) receptor (CD123); Leukemic stem cell (LSC)

Indexed keywords

ANTILEUKEMIC AGENT; CD123 ANTIGEN; CSL 360; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 3; MONOCLONAL ANTIBODY; STAT5 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CSL360;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTI LEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; EX VIVO STUDY; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; HYPOXIA; IMMUNOGENICITY; INFECTION; INFUSION RELATED REACTION; LEUKEMIA REMISSION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELENA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERLEUKIN-3; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84932085600     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.956316     Document Type: Article

References (39)

1. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in f rst relapse. J Clin Oncol 2005;23:1969-1978.
2. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-1098.
3. Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups def ned by mutations in NPM1, FLT3, and CEBPA. Blood 2010;115:948-956.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
5. Shlush LI, Zandi S, Mitchell A, et al. Identif cation of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.
6. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that dif er in self-renewal capacity. Nat Immunol 2004;5:738-743.
7. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002;99:16220-16225.
8. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
9. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777-1784.
10. Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD34+/CD38-stem cells in various myeloid malignancies. Leuk Lymphoma 2006;47:207-222.
11. Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001; 86: 1261-1269.
12. De Waele M, Renmans W, Vander Gucht K, et al. Growth factor receptor prof le of CD34 + cells in AML and B-lineage ALL and in their normal bone marrow counterparts. Eur J Haematol 2001;66:178-187.
13. Testa U, Riccioni R, Diverio D, et al. Interleukin-3 receptor in acute leukemia. Leukemia 2004; 18: 219-226.
14. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002;100:2980-2988.
15. Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004;72:89-106.
16. Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086-4092.
17. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11:6520-6527.
18. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009;5:31-42.
19. Vergez F, Green AS, Tamburini J, et al. High levels of CD34 + CD38low/-CD123 + blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011; 96: 1792-1798.
20. Sun Q, Woodcock JM, Rapoport A, et al. Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specif c IL-3 receptor antagonist. Blood 1996; 87: 83-92.
21. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
22. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
23. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
24. Wang JC. Evaluating therapeutic ef cacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 2007;1:497-501.
25. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med 2007;13:470-481.
26. Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica 2012;97:966-974.
27. Hauswirth AW, Florian S, Printz D, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123 + AML stem cells. Eur J Clin Invest 2007; 37: 73-82.
28. Bakker AB, van den Oudenrijn S, Bakker AQ, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004; 64: 8443-8450.
29. Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on dif erential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011;108:5009-5014.
30. Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specif c marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007;104:11008-11013.
31. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-299.
32. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-285.
33. Tsimberidou AM, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006; 132: 398-409.
34. Raza A, Jurcic JG, Roboz GJ, et al. Completeremissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma 2009; 50: 1336-1344.
35. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007;30:607-613.
36. Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specif c chimeric antigen receptor. Br J Haematol 2013; 161: 389-401.
37. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specif c chimeric antigen receptors exhibit specif c cytolytic Effector functions and antitumor Effects against human acute myeloid leukemia. Blood 2013;122:3138-3148.
38. Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modifed T cells. Blood 2014;123:2343-2354.
39. B u s f eld SJ, Biondo M, Wong M, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 2014 Apr 7. [Epub ahead of print]